Pharmaceutical

Meitheal gains rights to CONTEPO from Nabriva in North America

Meitheal Pharmaceuticals has gained rights to CONTEPO (fosfomycin for injection) from Nabriva Therapeutics for the North American region.

Jul 20, 2024 - 04:00
Meitheal gains rights to CONTEPO from Nabriva in North America
Meitheal Pharmaceuticals has gained rights to CONTEPO (fosfomycin for injection) from Nabriva Therapeutics for the North American region.
Read the original article

Tags:

Previous Article

Rona Therapeutics gains Series A+ funds for siRNA pipeline expansion

Next Article

EMA accepts Deciphera’s MAA cell tumour treatment for review

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Oft-prescribed beta blockers may not be wise for many heart patients

Oft-prescribed beta blockers may not be wise for many h...

May 3, 2023

Opinion: Good health care price transparency rules are at risk if Congress doesn’t act

Opinion: Good health care price transparency rules are ...

Mar 13, 2024

As midwife-assisted home births rise, so too do high-risk births outside hospitals

As midwife-assisted home births rise, so too do high-ri...

Feb 23, 2024